| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
|
Lancet Oncol
|
2014
|
5.89
|
|
2
|
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
|
Ann Oncol
|
2013
|
2.35
|
|
3
|
Circulating tumor cells as biomarkers in prostate cancer.
|
Clin Cancer Res
|
2011
|
2.17
|
|
4
|
Antibody-based therapeutics to watch in 2011.
|
MAbs
|
2011
|
2.00
|
|
5
|
Novel therapies for metastatic castrate-resistant prostate cancer.
|
J Natl Cancer Inst
|
2011
|
1.98
|
|
6
|
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.
|
J Clin Oncol
|
2011
|
1.94
|
|
7
|
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
|
Cancer Immun
|
2013
|
1.71
|
|
8
|
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.
|
Eur Urol
|
2011
|
1.64
|
|
9
|
The changing therapeutic landscape of castration-resistant prostate cancer.
|
Nat Rev Clin Oncol
|
2011
|
1.55
|
|
10
|
Castration-resistant prostate cancer: mechanisms, targets, and treatment.
|
Prostate Cancer
|
2012
|
1.47
|
|
11
|
Immunotherapy for the treatment of prostate cancer.
|
Nat Rev Clin Oncol
|
2011
|
1.12
|
|
12
|
Overview of the latest treatments for castration-resistant prostate cancer.
|
Nat Rev Urol
|
2013
|
1.12
|
|
13
|
Prostate cancer immunotherapy.
|
Clin Cancer Res
|
2011
|
1.11
|
|
14
|
Castration-resistant prostate cancer: latest evidence and therapeutic implications.
|
Ther Adv Med Oncol
|
2014
|
1.11
|
|
15
|
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.
|
J Immunol
|
2012
|
1.09
|
|
16
|
Current status of immunological therapies for prostate cancer.
|
Curr Opin Urol
|
2010
|
1.06
|
|
17
|
Emerging novel therapies in the treatment of castrate-resistant prostate cancer.
|
Can Urol Assoc J
|
2011
|
1.04
|
|
18
|
Molecular pathways and targets in prostate cancer.
|
Oncotarget
|
2014
|
1.00
|
|
19
|
Clinical impact of checkpoint inhibitors as novel cancer therapies.
|
Drugs
|
2014
|
0.99
|
|
20
|
Immune Infiltration and Prostate Cancer.
|
Front Oncol
|
2015
|
0.98
|
|
21
|
The changing landscape in the treatment of metastatic castration-resistant prostate cancer.
|
Ther Adv Med Oncol
|
2013
|
0.97
|
|
22
|
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.
|
Cancer Immunol Immunother
|
2011
|
0.97
|
|
23
|
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.
|
Ther Adv Urol
|
2014
|
0.96
|
|
24
|
Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
|
Nat Rev Urol
|
2012
|
0.93
|
|
25
|
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.
|
Cancer Immunol Immunother
|
2011
|
0.93
|
|
26
|
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.
|
J Transl Med
|
2013
|
0.93
|
|
27
|
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.
|
Prostate Cancer Prostatic Dis
|
2011
|
0.93
|
|
28
|
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
|
Curr Opin Oncol
|
2012
|
0.92
|
|
29
|
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy.
|
Oncogene
|
2013
|
0.91
|
|
30
|
Exploiting synergy: immune-based combinations in the treatment of prostate cancer.
|
Front Oncol
|
2014
|
0.91
|
|
31
|
Immunotherapy for prostate cancer: recent developments and future challenges.
|
Cancer Metastasis Rev
|
2014
|
0.90
|
|
32
|
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
|
Oncologist
|
2011
|
0.90
|
|
33
|
Unmasking the immune recognition of prostate cancer with CTLA4 blockade.
|
Nat Rev Cancer
|
2012
|
0.89
|
|
34
|
Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer.
|
Int J Oncol
|
2011
|
0.88
|
|
35
|
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
|
Int J Mol Sci
|
2013
|
0.88
|
|
36
|
Cell mates: paracrine and stromal targets for prostate cancer therapy.
|
Nat Rev Urol
|
2013
|
0.87
|
|
37
|
Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.
|
Ther Adv Vaccines
|
2014
|
0.86
|
|
38
|
Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.
|
Prostate Cancer Prostatic Dis
|
2014
|
0.86
|
|
39
|
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
|
Urol Oncol
|
2016
|
0.86
|
|
40
|
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
|
Cancer J
|
2013
|
0.84
|
|
41
|
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
|
Asian J Androl
|
2014
|
0.84
|
|
42
|
Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
|
Vaccine
|
2011
|
0.84
|
|
43
|
Emerging molecularly targeted therapies in castration refractory prostate cancer.
|
Prostate Cancer
|
2013
|
0.83
|
|
44
|
The current and emerging role of immunotherapy in prostate cancer.
|
Clin Genitourin Cancer
|
2010
|
0.83
|
|
45
|
Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report.
|
BMC Res Notes
|
2015
|
0.83
|
|
46
|
Emerging targeted therapies for castration-resistant prostate cancer.
|
Front Endocrinol (Lausanne)
|
2012
|
0.81
|
|
47
|
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
|
Oncologist
|
2015
|
0.81
|
|
48
|
Current status of immunological approaches for the treatment of prostate cancer.
|
Curr Opin Urol
|
2012
|
0.81
|
|
49
|
Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.
|
Ther Clin Risk Manag
|
2014
|
0.80
|
|
50
|
Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.
|
Clin Med Insights Oncol
|
2012
|
0.80
|
|
51
|
Beyond sipuleucel-T: immune approaches to treating prostate cancer.
|
Curr Treat Options Oncol
|
2014
|
0.79
|
|
52
|
Ipilimumab.
|
Drugs R D
|
2010
|
0.79
|
|
53
|
Unmet needs in the prediction and detection of metastases in prostate cancer.
|
Oncologist
|
2013
|
0.78
|
|
54
|
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.
|
Onco Targets Ther
|
2011
|
0.78
|
|
55
|
Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.
|
J Clin Immunol
|
2011
|
0.78
|
|
56
|
A changing landscape in castration-resistant prostate cancer treatment.
|
Front Endocrinol (Lausanne)
|
2012
|
0.78
|
|
57
|
Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'?
|
Oncology (Williston Park)
|
2014
|
0.78
|
|
58
|
Androgen pathway resistance in prostate cancer and therapeutic implications.
|
Expert Opin Pharmacother
|
2015
|
0.77
|
|
59
|
Immunotherapy for prostate cancer enters its golden age.
|
Clin Med Insights Oncol
|
2012
|
0.77
|
|
60
|
Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer.
|
Br J Cancer
|
2014
|
0.77
|
|
61
|
Immune Therapy for Prostate Cancer.
|
Cancer J
|
2016
|
0.76
|
|
62
|
Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer.
|
Cancer Biol Ther
|
2014
|
0.76
|
|
63
|
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?
|
Oncol Rev
|
2016
|
0.76
|
|
64
|
Immunotherapy in genitourinary malignancies.
|
Curr Opin Urol
|
2016
|
0.75
|
|
65
|
Management of metastatic castration-resistant prostate cancer.
|
Eur Urol Rev
|
2011
|
0.75
|
|
66
|
The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients.
|
P T
|
2012
|
0.75
|
|
67
|
Exciting Therapies Ahead in Prostate Cancer.
|
P T
|
2015
|
0.75
|
|
68
|
Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
|
Cancer Med
|
2013
|
0.75
|
|
69
|
Immune Checkpoint Therapies in Prostate Cancer.
|
Cancer J
|
2016
|
0.75
|
|
70
|
Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options.
|
P T
|
2014
|
0.75
|